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Available online 28 November 2013Emergence of SIV and HIV specific CD8 T cells has been shown to correlate with control of in vivo
replication. Poor correlation between IFN-γ ELISPOT responses and in vivo control of the virus has
triggered the development of more relevant assays to assess functional HIV-1 specific CD8 T-cell
responses for the evaluation and prioritization of new HIV-1 vaccine candidates. We previously
established a viral inhibition assay (VIA) that measures the ability of vaccine-induced CD8 T-cell
responses to inhibit viral replication in autologous CD4 T cells. In this assay, viral replication is
determined bymeasuring p24 in the culture supernatant. Here we describe the development of a
novel VIA, referred to as IMC LucR VIA that exploits replication-competent HIV-1 infectious
molecular clones (IMCs) in which the complete proviral genome is strain-specific and which
express the Renilla luciferase (LucR) gene to determine viral growth and inhibition. The
introduction of the luciferase readout does provide significant improvement of the read out time.
In addition to switching to the LucR read out, changes made to the overall protocol resulted in the
miniaturization of the assay from a 48 to a 96-well plate format, which preserved sample and
allowed for the introduction of replicates. The overall assay time was reduced from 13 to 8 days.
The assay has a high degree of specificity, and the previously observed non-specific background
inhibition in cells fromHIV-1 negative volunteers has been reduced dramatically. Importantly, we
observed an increase in positive responses, indicating an improvement in sensitivity compared to
the original VIA. Currently, only a limited number of “whole-genome” IMC-LucR viruses are
available and our efforts will focus on expanding the panel to better evaluate anti-viral breadth.
Overall,we believe the IMC LucRVIA provides a platform to assess functional CD8 T-cell responses
in large-scale clinical trial testing, which will enhance the ability to select the most promising
HIV-1 vaccine candidates capable of controlling HIV-1 replication in vivo.
© 2013 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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The emergence of specific CD8 T cells has been shown to
correlate with in vivo control of HIV and SIV replication (Koup
et al., 1994; Harrer et al., 1996; Goulder et al., 1997; Cohen et
al., 2011). These observations suggest that a functional HIV-1
vaccine aimed at inducing a protective immune response
should elicit an effective CD8 T-cell response. Therefore,
standardizable assays that assess HIV-1 specific CD8 effector
T-cell responses elicited by vaccine immunogens are important
for evaluating HIV-1 vaccine candidates, especially in early
phase clinical trials, as a means to help select the most
promising candidates. The IFN-γ enzyme-linked immunospot
(ELISPOT) assay is most commonly used to determine HIV-1
specific CD8 T-cell responses. However, the expression of
cytokines such as IFN-γ, asmeasured in the ELISPOT assay, is an
indirect measure of CD8 T-cell induced inhibition of HIV-1
replication.Moreover, the requirement of the ELISPOT assay for
high levels of exogenous peptides limits evaluation of overall
HIV-1 responses (Bennett et al., 2008; Valentine et al., 2008).
Recent studies have revealed a poor correlation between IFN-γ
ELISPOT responses and in vivo control of HIV-1 replication
(Lieberman, 2004; Valentine et al., 2008; Gray et al., 2009).
Together these observations illustrate the need for an in vitro
assay that correlates better with HIV-1 specific effector CD8
T-cell responses in vivo.
We and others have previously developed a viral inhibition
assay (VIA) thatmeasured inhibition of HIV-1 in infected CD4 T
cells in co-culture with autologous CD8 T cells, in vitro.
(Gauduin et al., 1998; Loffredo et al., 2005; Fauce et al., 2007;
Tsukamoto et al., 2007; Chen et al., 2009; Saez-Cirion et al.,
2010; Spentzou et al., 2010; Akinsiku et al., 2011; Freel et al.,
2012; Yamamoto et al., 2012). The observed inhibition of HIV-1
replication could be the result of HIV-1 specific major
histocompatibility complex (MHC) dependent cytolytic CD8
T-cell activity (Toso et al., 1995; Yang et al., 1997; Migueles et
al., 2008) as well as non-cytolytic mechanisms (Walker et al.,
1991; Cocchi et al., 1995; Tomaras et al., 2000; Freel et al.,
2012) or a combination of both. The VIA has the potential tomeasure the overall viral suppression induced by a combina-
tion of both mechanisms, which results in a more relevant
readout of HIV-1 specific CD8 T cell responses than the IFN-γ
ELISPOT. In addition, using a panel of viruses in the VIA allows
for the assessment of the breadth of suppression.
The VIA protocol varies between different laboratories
although most commonly the amount of de novo produced
HIV p24 or SIV p27 concentration in the culture supernatant
of in vitro infected CD4 T-cells is determined by ELISA as a
measurement of viral replication or inhibition in the presence
of CD8 T-cells (Gauduin et al., 1998; Fauce et al., 2007;
Tsukamoto et al., 2007; Chen et al., 2009; Spentzou et al.,
2010; Yamamoto et al., 2012). Other methods to determine
viral inhibition include p24 intracellular staining (ICS)
(Loffredo et al., 2005; Saez-Cirion et al., 2010) or indirect
measurements, such as luciferase expression after infection
of TZM-bl cells with the VIA culture supernatants (Akinsiku
et al., 2011; Freel et al., 2012).
Our initial efforts have focused on the development of a VIA
that determines the p24 release in cell culture supernatant as a
measure of HIV-1 replication, and this assay has proven
valuable for testing samples from several HIV-1 vaccine trials
(Spentzou et al., 2010; Hayes et al., 2013; Borthwick et al.,
2013). However, we recognized certain limitations and thus
pursued technological advances towards the development and
optimization of a second generation VIA, referred to through-
out themanuscript as the IMC LucR VIA. The goalwas to reduce
the number of cells needed, increase assay sensitivity and
specificity, and decrease time and overall cost to perform the
assay. The international AIDS Vaccine Initiative (IAVI) in
collaboration with the Collaboration for AIDS Vaccine Discov-
ery (CAVD) funded consortia, the Comprehensive T Cell
Vaccine Immune Monitoring Consortium (CT-VIMC) and the
Comprehensive Antibody Vaccine Immune Monitoring Con-
sortium (CA-VIMC) achieved this goal through the combina-
tion of our VIA assay platform (developed within IAVI) with
enabling Renilla reniformis luciferase (LucR) reporter HIV-1
technology (developed within CHAVI). We previously de-
scribed and validated a LucR reporter HIV-1 approach utilizing
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encoding heterologous env gene sequences of choice (Edmonds
et al., 2010; Montefiori et al., 2012). While utility of
NL-LucR.T2A-based replicating reporter viruses (collectively
referred to as Env-IMC-LucR) in the VIA has been demonstrated
(Freel et al., 2010), this approach was limited by the isogenic
nature of these viruses outside of env; thus, strain-specific
differences in VIA responses mapped solely to the different
heterologous envelope genes. In the work presented here, we
thus utilized a novel LucR expressing, replication-competent
infectious molecular clone (IMC) which encompasses the full-
length strain-specific genome of the transmitted/founder (T/F)
HIV-1, CH077.t,whichwe recently described (Ochsenbauer et al.,
2012). Application of CH077.t-LucR, and similarly constructed
relevant strains of reporter allow the comparison of VIA
responses against all viral genes, therefore allowing a much
broader comparison of CD8 T cell responses between different
samples tested.
This manuscript describes the successful development of the
IMC LucR VIA by implementing a fast, less labor intensive and
more cost effective luciferase read out. Optimization of the assay
allowed for miniaturization from a 48 well to a 96-well plate
format, allowing for the introduction of replicates. The IMC LucR
VIA exhibits high specificity and a significantly reduced non-
specific background inhibition, enhancing the interpretation of
the assay which is important for the implementation into HIV-1
vaccine trials.2. Material and methods
2.1. Cells
TZM-bl cells were obtained from theNIHAIDS Research and
Reference Reagent program (NIH ARRRP) (ARP5011), as
contributed by John Kappes and Xiaoyun Wu. 293T/17 cells
were obtained from the American type culture collection
(ATCC) (CRL11268). Both cell lines were maintained in
Dulbecco's modified Eagle's medium (DMEM) with 10% heat
inactivated fetal bovine serum (FBS) (Sigma, UK), penicillin
(100 U/ml) (Sigma, UK) and streptomycin (100 U/ml) (Sigma,
UK).
PBMCs were isolated by density centrifugation and
frozen in 10% dimethylsulphoxide (DMSO) (Sigma, UK)/
90% FBS and stored in vapor phase liquid nitrogen. PBMCs
were cultured in RPMI 1640 containing 30 U/ml recombi-
nant human IL-2 (Roche, Germany), penicillin (100 U/ml)
and streptomycin (100 U/ml). All samples were collected
under informed consent and studies were approved by
the relevant local ethics committees. Samples in London
were stored in a Human Tissue Act (HTA) registered
Biorepository (License 12560). PBMCs from long term
nonprogressors (LTNP) and elite controllers (EC) were
kindly provided by Bruce Walker, Harvard, Boston, USA.
HIV-1 positive PBMCs were provided by Dr. O. Anzala, Kenya
AIDS Vaccine Initiative from patient with plasma viral load
below 10,000 copies/ml and ART untreated for a minimum
of six months. The HIV-1 sero-negative PBMCs were
obtained from South African National Blood Transfusion
Services, South Africa. The HIV-1 vaccine trial samples are of
two clinical trials conducted by IAVI and/or collaboratorswith vectors expressing a variety of HIV-1 genes (Jaoko et
al., 2010; Borthwick et al., 2013).
2.2. Proviral plasmid construction
We have previously described the construction of
NL-LucR.T2A and NL-LucR.T2A-CH077.ecto (Edmonds et al.,
2010) in which the R.reniformis luciferase reporter gene
(GenBank accession AF362549) was introduced into the
HIV-1 lab strain NL4.3 genome in between the env and nef
genes, followed by a T2A self-cleavage site.
We previously generated the clade B T/F IMC, CH077.t
(Ochsenbauer et al., 2012), which represents the proviral
genome sequence of the HIV-1 founder virus that established
clinical infection in subject 700010077 from the CHAVI-001
Acute Infection Cohort (Salazar-Gonzalez et al., 2009). We
introduced the LucR-T2A reporter gene cassette to generate
CH077.t-LucR.T2A, essentially mirroring the molecular design
for NL-LucR.T2A. Briefly, we identified suitable unique restric-
tion sites upstream of the env gene (EcoRI, nt 5770) and
downstream of nef (MluI, in the plasmid vector sequence
adjacent to the end of the 3′ LTR) and designed forward and
reverse primers, respectively, just 5′ and just 3′ of these sites
(Fwd.Eco; Rev.Mlu).We furthermore designed a reverse primer
overlapping the 3′ end of env, and extending the sequence to
include an NheI and XbaI site (Rev. Nhe-Xba.env), essentially as
described previously. A forward primer (Fwd.Nhe-Xba.nef)
overlapping with nef and introducing the same sites 5′ of the
nef ATG was also designed; these reverse and forward primers
overlapped in the sequence containing the NheI and XbaI
sites. We then amplified the fragments including env and nef,
respectively, using pCH077.t as template DNA, and subjected
the amplicons to a fusion PCR reaction utilizing primers Fwd.Eco
and Rev. Mlu. The resulting amplicon spanning from EcoRI
through env, the Nhe-Xba linker, nef, the 3′LTR, to MluI was
then TA-cloned into pCR4-TOPO cloning vector (Invitrogen).
We then excised the LucR.T2A coding sequence from
NL-LucR.T2A using the engineered NheI and XbaI restriction
sites, and inserted it between the NheI and XbaI sites of
the TA-cloned subgenomic fusion PCR amplicon cloning
intermediate. After sequence confirmation, the entire EcoRI
through MluI fragment encompassing the env-NheI-Kozak-
LucR.T2A-Xba-nef cassette was excised and ligated into
EcoRI/MluI digested pCH077.t. The entire proviral sequence
of maxi-prepped plasmid DNA of pCH077.t-LucR.T2A was
confirmed by sequencing reaction and trace analysis with
Sequencher software (Gene Codes Corporation, Ann Arbor,
MI).
2.3. Generation of virus stocks and determination of infectivity
All IMC virus stocks were generated by transfection of
293T/17 cells as previously described (Ozaki et al., 2012). In
short 3–5 × 106 293T/17 cells were seeded in a T75 culture
flask the day before transfection. Twelve microgram of DNA
in DMEM was transfected using FuGENE 6 (Promega, UK)
according to manufacturer's instructions. After 4 to 6 h the
transfection medium was replaced with fresh medium. The
supernatant was harvested and filtered after 48 h and
aliquots were stored at −80 °C until use.
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as previously described (Ozaki et al., 2012). In short, 1 × 105
TZM-bl cells per well were infected with a serial dilution of the
virus stock in quadruplicate, startingwith a 1/10 dilution in the
presence of 10 μg DEAE Dextran (Sigma, UK) per ml.
Forty-eight hours later the firefly luciferase expressed by the
TZM-bl cells was determined with Britelight Plus reagent
(PerkinElmer, UK). The relative light units (RLU) were
measured on an Infinite M200Pro plate reader (Tecan, UK).
Alternatively, the virus stocks used to determine the replication
kinetics (Fig. 1) were also titered on the TZM-bl reporter cell
line to determine infectious units/ml by enumeration of
β-galactosidase (β-gal) stained colonies as described previous-
ly (Wei et al., 2002).
2.4. Replication kinetics determination
Defrosted PBMCs were cultured as previously described
(Spentzou et al., 2010) for 7 days at a concentration of 1 to
1.5 × 106 cells/ml in RPMI 1640 containing 30 U/ml recombi-
nant human IL-2, penicillin (100 U/ml) and streptomycin
(100 U/ml). CD3/CD8 bi specific antibodies (0.5 μg/ml)
(Wong and Colvin, 1987) were added to the culture medium
to expand the CD4 T cell population. For each virus, 1.5 × 106 of
pooled and expanded CD4 T cells from 5 different HIV-1
negative donors were infected with 0.1 MOI (as based on the
TCID50 determination) in a 24 well plate format. The CD4 T
cells were pooled at 1:1 ratio based on the cell counts on the
day of infection. After 4 h of incubation at 37 °C theFig. 1. Virus characterization. (A) Infection of HIV negative CD4 T cells with NL4
determined in the culture supernatant (ELISA). (B) Infection kinetics of HIV negative
activity in the cells as read-out at different time points during replication. (C & D
infectivity for luciferase containing IMCs. HIV negative CD4 T cells were infected w
time points (depicted on the X-axis). The supernatants were used to infect TZM
luciferase (expressed by the TZMbl cells upon infection) is depicted. (C) NL-LucR.Tsupernatant was replaced with fresh medium. Supernatant
was collected every 3 to 4 days and stored at −80 °C and an
equal volume of fresh medium was added to replenish the
cultures. The concentration of p24 was determined by
enzyme-linked immunosorbent assay (ELISA) (PerkinElmer,
UK). The luciferase activity was determined by Renilla Glo
luciferase assay system (Promega, UK) in accordance with
manufacturer's instructions.
2.5. Determination of Renilla Luciferase stability
The stability of the R. reniformis luciferase reporter genewas
determined as previously described (Edmonds et al., 2010).
Briefly, 1.5 × 106 pooled (5 different donors) CD4 T cells
expanded by CD3/CD8 bi-specific antibodies (Wong and
Colvin, 1987) as described above were infected with 0.1 MOI
for each virus for a period of 13 days. Supernatant was
collected at different time points after infection, cleared from
cells by centrifugation, and stored at−80 °C. TZM-bl cellswere
plated at a concentration of 1 × 104 cells/well in a 96 well
format and infected with different volumes of supernatant
collected from the PBMC cultures (0.2, 1, 5 or 10 μl) in the
presence of 10 μg/ml DEAE Dextran (Sigma, UK). After 4 h of
the supernatants were replaced with fresh medium after an
additional 18 h 5 μMreverse transcriptase inhibitor Nevirapine
(Sigma, UK) was added to all cultures. After an additional 18 h
of incubation the Renilla and firefly luciferase activity was
determined by the Dual-Luciferase Reporter Assay System
(Promega, UK) in accordancewithmanufacturer's instructions..3, NL-LucR.T2A, CH077.t and CH077.t-LucR T2A. P24 concentrations were
CD4 T cells with NL-LucR.T2A and CH077.t-LucR T2A using Renilla Luciferase
) Determination of stability of Renilla luciferase expression relative to viral
ith the luciferase containing virus and supernatant was collected at different
bl cells. The ratio between virus-encoded Renilla and cell-encoded firefly
2A (D) CH077.t-LucR T2A.
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determined and compared to the ratio of the stock used to
infect the CD4 T cells, to assess the stability of the Renilla
Luciferase gene in the viral genome over time.
2.6. First generation VIA p24 and luciferase read out
Defrosted PBMCs were cultured as previously described
(Spentzou et al., 2010) for 7 days at a concentration of 1–
1.5 × 106 cells/ml in RPMI 1640 containing 30 U/ml recom-
binant human IL-2, penicillin (100 U/ml) and streptomycin
(100 U/ml). CD3/CD4 or CD3/CD8 bi specific antibodies
(0.5 μg/ml) (Wong and Colvin, 1987) were added to the
culture medium to expend the CD8 or CD4 T-cell population,
respectively. Fresh mediumwas added every 3 to 4 days. Half
a million per well expanded CD4 T cell population were
infected with IIIB produced on PBMCs or CH077.t IMC
produced by transfection, at an MOI of 0.01 in a 48 well
plate. The CD4 T cells were cultured over a period of 13 days
with or without autologous CD8 T cells at a 1:1 ratio. Half
of the culture supernatant was replaced by fresh medium
every 3 to 4 days. Viral replication was determined 13 days
post-infection by p24 ELISA (PerkinElmer). The log inhibition
was determined by subtracting the log10 p24 concentration
of the CD4 CD8 T cell co-culture from the log10 p24
concentration determined for the culture of CD4 T cells
alone. Alternatively, expanded CD4 T cells were infected
with, NL-LucR.T2A and CH077.t-LucR.T2A at an MOI of 0.01.
The cells were plated in triplicate wells at a concentration of
0.1 × 106 cells per well in a 96 well format. The CD4 T cells
were cultured alone or in the presence of autologous CD8 T
cells at a 1:1 ratio. After 13 days 100 μl supernatant was used
to determine the p24 concentrations by ELISA (PerkinElmer)
and the luciferase activity in the same well was determined
by Renilla-Glo Luciferase assay system (Promega).
2.7. IMC LucR VIA
The CD8 and CD4 T cell population were generated and
expanded over 7 days by the addition of bi-specific antibod-
ies identical to the first generation VIA. On day 7 the CD4 cells
were counted and infected with NL-LucR.T2A or CH077.t-
LucR.T2A at an MOI of 0.01 (based on TZM-bl TCID50) by
spinoculation (1800 ×g, 2 h, RT) at a cell concentration of
10 × 106 cells/ml in RPMI 1640 containing 30 U/ml recom-
binant human IL-2, penicillin (100 U/ml) and streptomycin
(100 U/ml). After the spinoculation fresh mediumwas added
to dilute the cells to a concentration of 1 × 106 cells/ml. On
the same day, fresh medium was added to the expanded CD8
T-cells. Both the infected CD4 and CD8 were incubated for
an additional 3 days at 37 °C. Cells were then counted and
0.1 × 106 infected CD4 T cells per well were seeded in
triplicate in a 96 well format with or without CD8 T cells at a
1:1 ratio, unless indicated otherwise. Cells were then
incubated for an additional 5 days. Luciferase activity was
determined with the Renilla-Glo Luciferase assay system
(Promega) as a measure of viral infection. The log inhibition
was determined by subtracting the log10 relative light units
(RLU) of the CD4 CD8 T cell co-culture from the log10 RLU
determined for the culture of CD4 T cells alone.3. Results
3.1. Virus characterization
Currently used VIA platforms have limitations with
regard to cost, required sample volumes, time, sensitivity
and specificity. To overcome these obstacles and develop a
more efficient, sensitive and cost-effective VIA we intro-
duced replication-competent Renilla luciferase reporter
HIV-1 infectious molecular clones (IMC) to the VIA. Our
rational was that the introduction of the NL-LucR.T2A-based
Env-IMC-LucR viruses has greatly advanced applications in
the HIV-1 neutralizing antibody field which faces similar
challenges (Edmonds et al., 2010; Brown et al., 2012;
Montefiori et al., 2012; Pace et al., 2013), Env-IMC-LucR
viruses have been used for proof of principle in CD8 VIA
(Freel et al., 2010), which illustrates that VIA appropriate
adaptation of the molecular approach can be achieved. We
chose the IMC of clade B T/F HIV-1,CH077.t (Ochsenbauer et
al., 2012), as a relevant HIV-1 strain to introduce the LucR
reporter gene, and generated CH077.t-LucR.T2A. To deter-
mine the implications for the introduction of the reporter
gene into the T/F IMC, we compared the replication curves
of both LucR containing viruses with their parental the wild
type viruses. P24 production in both LucR reporter viruses
infected cultures was reduced compared to wild-type
viruses after day three (Fig. 1A), indicating less efficient
replication after the first round of infection, essentially as
described (Edmonds et al., 2010). The LucR reporter viruses
showed similar replication kinetics based on the p24 read
out, which is confirmed by the replication curves based on
the measurement of the LucR activity (Fig. 1B). The VIA
involves several rounds of replication in CD4 T cells,
therefore it was important to establish the stability of LucR
gene expression over time since reduction of the LucR
reporter activity due to elimination of the LucR gene from
the proviral genome over time could negatively affect the
interpretation of the IMC LucR VIA. Stability of the reporter
gene was determined by infecting expanded CD4 T cells
with the reporter viruses over a period of 13 days while
supernatant was collected on day 7, 10 and 13. The
supernatants were frozen at −80 °C until used to infect
TZM-bl cells, which express cell-encoded firefly luciferase
upon HIV-1 infection thereby providing a means to normal-
ize LucR levels to relative infectivity. Therefore, the ratio
between Renilla and Firefly luciferase at different time
points can be compared to the original virus stock ratio,
to determine stability and retention of the LucR in the
proviral genomes after several cycles of replication. Both
NL-LucR.T2A and CH077.t-LucR.T2A (Fig. 1C and D, respec-
tively) showed relatively stable RLU ratios even though a
slight reduction of Renilla luciferase expression is observed
at day 13, essentially as previously reported for NL-LucR.T2A
(Edmonds et al., 2010) and illustrating that the LucR
expression from both the NL-derived as well as the T/F IMC
reporter virus is stable over the course of the IMC LucR VIA
experiment. Even when CH077.t-LucR.T2A infected PBMC
cultures were followed for 31 days, reduction of the Renilla
Luciferase RLU to Firefly luciferase RLU ratio at the end point
was only about 4-fold, and about 20% by day 12 and 18 (data
not shown).
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Comparison of the replication kinetics in CD4 T cells in the
presence or absence of CD8 T cells was performed for the two
reporter viruses in a panel of PBMCs obtained from HIV-1
negative, HIV-1 positive long term non-progressor (LTNP) and
elite controller (EC) volunteers in the first generation VIA with
the LucR read-out. Representative replication curves obtained
using both the p24 and Luciferase read out are shown in
Fig. 2A–D for the infection of cells fromoneHIV-1 positive LTNP
and one HIV-1 negative donor with CH077.t-LucR.T2A. The
replication curves in CD4 T cells derived from a HIV-1 positive
LTNP in the absence or presence of the autologous CD8 T cells
are similar between the p24 and luciferase read out (Fig. 2AFig. 2. Correlation between p24 and Luciferase read out. (A–D) An example of the
infecting with CH077.t-LucR T2A. (A) Replication in HIV-1 negative CD4 T cells, in th
in the culture supernatant. (B) Replication in HIV-1 negative CD4 T cells, in the p
(C) Replication in HIV-1 positive CD4 T cells, in the presence or absence of autol
(D) Replication in HIV-1 positive CD4 T cells, in the presence or absence of autologo
Luciferase read out for both NL-LucR T2A and CH077.t-LucR T2A. The data is com
correlation was determined.and B, respectively). Again, good concordance was observed
when comparing the two read outs for the infection kinetics
when using cells from a HIV-1 negative volunteer (Fig. 2C and
D), where limited inhibition was observed in the presence of
the autologous CD8 T cells. To further validate our observations
we performed a correlation analysis between the log10 p24
and log10 LucR read out by combining results of four separate
experiments performed in triplicate (Fig. 2E). Expanded CD4 T
cells from LTNP, EC&HIV-1negative donorswere infectedwith
NL-LucR.T2A or CH077.t-LucR.T2A and cultured in the presence
or absence of autologous CD8 T cells. Both the p24 concentra-
tion in the culture supernatant and the LucR expression in the
cultured cells were determined at multiple days within each
experiment. A highly significant correlation was observedreplication curves based on the p24 and luciferase read out in the VIA when
e presence or absence of autologous CD8 T cells, based on p24 concentrations
resence or absence of autologous CD8 T cells, based on luciferase read out.
ogous CD8 T cells, based on p24 concentrations in the culture supernatant.
us CD8 T cells, based on Luciferase read out. E. Correlation between p24 and
bined from 4 independent experiments with a total N of 172. The Pearson
167M.A. Naarding et al. / Journal of Immunological Methods 409 (2014) 161–173between the log10 p24 and the log10 LucR RLU. Altogether, our
data support that changing the assay read-out fromp24 to LucR
yield similar results for the replicating kinetics of the viruses as
well as the level of viral inhibition observed.
3.3. Optimization of the IMC LucR VIA
We proceeded to further optimize the VIA to fully realize
the potential of the IMC LucR VIA. To increase infection of the
CD4 T cells we introduced a spinoculation step followed by an
incubation of 3 days before addition of expanded autologous
CD8 T cells, thereby allowing for a persistent infection of the
CD4 T cells prior to addition of the CD8 T cells. The luciferase
activity is determined 5 days after addition of the CD8 T cells,
resulting in a decrease of 5 days in overall assay time. In
addition the assaywasminiaturized to a 96well format instead
of a 48 well plate (as in the 1st generation). This resulted in
fewer cells per well being used and therefore allowing for the
introduction of more replicates.
We then investigated the effect of CD8:CD4 ratio in the
IMC LucR VIA. The log inhibition was determined for different
CD8 and CD4 T-cell ratios for a HIV-1 negative volunteer for
NL-LucR.T2A and CH077.t-LucR.T2A (Fig. 3A and B, respec-
tively). Little to no inhibition was observed at the 1:1 or
lower cell ratio for both viruses. However, non-specific
inhibition increased proportionally with ratios over 1:1. In
the HIV-1 positive PBMCs, the extent of the specific inhibition
for NL-LucR.T2A (Fig. 3A) and CH077.t-LucR.T2A, (Fig. 3B)Fig. 3. The influence of CD8-CD4 T cell ratio on the level of non-specific inhibition in
log inhibition was determined by subtracting the average RLU for infected CD4 cells
from a HIV-1 negative donor and the hashed bars represent the results when using
The data is from a representative experiment, repeated 3 times. (C) The effect of C
inhibition is shown. The data is determined on PBMCs from 9 different HIV-1 nega
combined. (D) The log inhibition was determined on PBMCs from 8 HIV-1 positive
T2A and CH077.t-LucR T2A were combined. Both box and whiskers graphs represe
maximum and minimum values are depicted as the whiskers. A paired T-test was pdecreased slightly when the CD8:CD4 T-cell ratio decreased,
but the effect is much less pronounced than that observed for
non-specific inhibition in the HIV-1 negative PBMCs.
To determine if the increase of non-specific inhibition
associated with an increase of CD8 T cells is a reoccurring
phenomenon, we tested another eight HIV-1 negative and
eight HIV-1 positive donors (Fig. 3C and D respectively) and
combined the results from both viruses. The results showed
that the non-specific background inhibition was consistently
and significantly higher (P b 0.0001, paired T test; increased
by 0.8 log) when the CD8:CD4 ratio was increased (Fig. 3C).
The same was observed for the specific inhibition using HIV-1
positive samples, although this effect was less pronounced
(P = 0.0005, paired T test; increased by 0.4 log) (Fig. 3D).
Determination of the coefficient of variation (CV) across the
HIV-1 positive samples revealed a large difference in
variability between the 1:1 and 10:1 cell ratio. The 1:1 cell
ratio had a CV of 52.84% whereas the 10:1 cell ratio had a CV
of 23.86%, illustrating a decrease in variability within this
group indicating an undesirable decreased range and ability
to distinguish the log inhibition differences between different
volunteer PBMCs. In addition, the reduction of non-specific
background inhibition in the VIA could have positive
implication for the sensitivity of the assay. In summary, the
optimization process allowed us to decrease assay time by
5 days, decrease number of cells used by miniaturization and
select the optimal CD8:CD4 ratio of 1:1. All these changes
were incorporated in the IMC LucR VIA.the IMC LucR VIA. (A & B) The experiment was performed in triplicate and the
+ CD8 T cells from infected CD4 T cells. The black bars represent the PBMCs
PBMCs from a HIV-1 positive donor. (A) NL-LucR.T2A (B) CH077.t-LucR.T2A.
D8 & CD4 T cell ratio in the IMC LucR VIA on the non-specific background
tive volunteers and the results for NL-LucR T2A and CH077.t-LucR T2A were
volunteers for different CD8 & CD4 T cell ratios. The results for both NL-LucR
nt the 95 percentile, the median is depicted by the line in the box and the
erformed using GraphPad Prism version 5 to determine significance.
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using samples from HIV-1 vaccine trials
The results obtained with the first generation VIA utilizing
the p24 read out system (Spentzou et al., 2010) were
compared to those from the newly developed IMC LucR VIA
using PBMCs from several HIV-1 vaccine trials. The log
inhibitions for the first generation VIA and the IMC LucR
VIA were determined and compared. We compared IIIB to
NL-LucR.T2A and CH077 to CH077.t-LucR.T2A for the first
generation VIA and the IMC LucR VIA, respectively. NL 4.3 is
derived from IIIB and therefore the viruses share a high
degree of sequence homology (98% homology when com-
paring sequenced IIIB to NL 4.3 (AF324493), data not shown).
The results of the assay comparison for both viruses using
pre-immunization PBMCs from twenty eight vaccine trial
volunteers revealed a significant reduction (P b 0.0001,
Wilcoxon matched pairs test) of the non-specific background
inhibition in the IMC LucR VIA when compared to the first
generation (Fig. 4A). These results allowed us to determine
the assay cutoff for the IMC LucR VIA at 0.6 log inhibition, as
calculated by the mean log inhibition plus 3 standard
deviations, (represented as a dashed line in Fig. 4A). InFig. 4. Comparison of the non-specific background inhibition between the first ge
CH077 was compared to CH077.t-LucR T2A for the first generation VIA and the IMC
time points and the results from NL-LucR T2A and CH077.t-LucR T2A were comb
performed using GraphPad Prism version 5 to determine significance. The box and w
in the box and the maximum and minimum values are depicted as the whiskers. Th
determined between the first generation VIA and the IMC LucR VIA for both virus co
different time points, varying from before or after immunization. The vertical and h
IMC LucRVIA, respectively. A Pearson correlation was performed using GraphPad Pri
the linear regression.contrast, a higher cut-off of 1.4 log inhibition was calculated
for the first generation in line with the previously observed
value of 1.5 log inhibition (represented as a dashed line in
Fig. 4A) (Jaoko et al., 2010; Spentzou et al., 2010; unpub-
lished data). A comprehensive comparison of the first
generation VIA and the IMC LucR VIA was performed using
sixty-seven pre- and post vaccination PBMCs from forty
volunteers participating in two different HIV-1 vaccine trials
(Fig. 4B) (Jaoko et al., 2010; N Borthwick et al. manuscript in
preparation). Results obtained for both virus combined
showed a significant correlation (P b 0.0001, Pearson corre-
lation) between the two assays. Two PBMC samples showed
inhibition in the first generation VIA but not in the IMC LucR
VIA. On the contrary, seventeen samples did not inhibit in the
first generation VIA but did in the IMC LucR VIA, which could
indicate an increased sensitivity of the IMC LucR VIA, but
additional screening need to be performed to confirm this.
Importantly, the responses of placebo treated volunteers
as well as all pre-immunization samples were below the
specific cutoff for both VIAs indicating a high specificity of
both VIAs. In both the first generation VIA and the IMC LucR
VIA there were more responses to IIIB and NL-LucR.T2A than
to CH077 and CH077.t-LucR.T2A. Positive responses to CH077neration VIA and the IMC LucR VIA. IIIB was compared to NL-LucR T2A and
LucR VIA, respectively. (A) The PBMCs used were all from pre-immunization
ined, resulting in an N of 56 (N = 28 for each virus). A paired T test was
hiskers graph represent the 95 percentile, the median is depicted by the line
e cutoff for each assay are depicted as a dotted line. (B) The correlation was
mparisons combined. The data is comprised of data from 40 patients and 68
orizontal dotted lines represent the cutoff of the first generation VIA and the
sm version 5. Depicted in the graph by the dashed line is the standard error of
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responses to IIIB and NL-LucR.T2A, respectively.
3.5. Speciﬁcity and interassay variability of the IMC LucR VIA
Interassay variability was determined on eight different
HIV-1 positive PBMCs and nine HIV-1 negative PBMCs
infected with NL-LucR.T2A or CH077.t-LucR.T2A in four to
six independent experiments (depending on the sample)
performed in triplicate by two different operators (Fig. 5).
Comparison of the maximum infection of HIV-1 positive CD4
T cells for NL-LucR.T2A and CH077.t-LucR.T2A (Fig. 5A and B,
respectively) revealed a high consistency of results between
experiments and operators The same was observed when
determining the maximum of infection in HIV-1 negative
CD4 T cells for NL-LucR.T2A and CH077.t-LucR.T2A (Fig. 5C
and D, respectively). The maximum infection was donor
dependent since it was consistent across individual experi-
ments and operators. The intradonor coefficient of variations
of the log10 RLU varied from 2.33% to 14.75% with a mean of
7.90% for the HIV-1 positive cells for both viruses combined.
The same range was observed for the HIV-1 negative cells for
both viruses combined, which varied from 2.21% to 12.94%
with a mean of 7.17%. Overall these results demonstrate a
low variability of infection between separate experiments
and operators, which is of note since this is a complex
primary cell culture based assay with multiple steps which
could potentially introduce variability. In addition, results
indicated that there is no difference in infection ratesFig. 5. Assay variability for the infection of CD4 T cells of the IMC LucR VIA. The rate o
different operators is depicted for each donor. Eight HIV-1 positive and nine HIV-
individuals infected with NL-LucR T2A. (B) Cells derived from HIV-1 positive individ
individuals infected with NL-LucR T2A. (D) Cells derived from HIV-1 negative individ
the 95 percentile, the median is depicted by the line in the box and the maximum a
whiskers all individual data points are shown as dots.between HIV-1 positive and negative samples. The HIV-1
positive samples used in these experiments are from patients
with plasma viral loads below 10,000 copies/ml, indicating
that the CD4 T cell population in these patients is not
compromised, thereby having limited effect on the infection
efficiencies of these cells. It is also important to keep in mind
that the VIA is primarily developed to determine HIV-1
specific T cell responses in HIV-1 vaccinated individuals not
in HIV-1 infected individuals, even though the assay could
also be used to determine correlates of protection by
comparing HIV-1 infected and uninfected individuals.
Subsequently we determined the CD8 T-cell induced log
inhibitionwithin the sameexperiments described above. CD8 T
cells from HIV-1 positive PBMCs for NL-LucR.T2A and
CH077.t-LucR.T2A (Fig. 6A and B, respectively) show a range
in inhibition. The intradonor coefficient of variation for these
samples varied from 21.45% to 62.14% with a mean of 40.80%
for both viruses combined. In addition, the CVs for each
individual IMC were not statistically different. The log inhibi-
tion was also determined for PBMCs from nine HIV-1 negative
volunteers for NL-LucR.T2A and CH077.t-LucR.T2A (Fig. 6C and
D, respectively). The log inhibitions fell below the previously
established cut-off of 0.6 log inhibition for all except one
experiment with PBMCs from donor 17 for NL-LucR.T2A and in
another experiment for CH077.t-LucR.T2A, illustrating that the
observed false positives were not the results of an error in one
specific experiment. The intradonor coefficient of variability
was not determined because most means were around zero,
which would result in high CVs that do not represent relevantf infection of CD4 T cells in 4 to 6 independent experiments performed by two
1 negative donor PBMCs were tested (A) Cells derived from HIV-1 positive
uals infected with CH077.t-LucR T2A. (C) Cells derived from HIV-1 negative
uals infected with CH077.t-LucR T2A. The box and whiskers graphs represent
nd minimum values are depicted as the whiskers. In addition to the box and
Fig. 6. Assay specificity and interassay variability for the log inhibition of the IMC LucR VIA. The log inhibition of 4 to 6 independent experiments performed by
two different operators is depicted for each donor. The log inhibition was determined by subtracting the average RLU of the triplicates in each experiment for
infected CD4 cells + CD8 T cells from infected CD4 T cells alone. Eight HIV-1 positive and nine HIV-1 negative donor PBMCs were tested. (A) Cells derived from
HIV-1 positive individuals infected with NL-LucR T2A. (B) Cells derived from HIV-1 positive individuals infected with CH077.t-LucR T2A. (C) Cells derived from
HIV-1 negative individuals infected with NL-LucR T2A. (D) Cells derived from HIV-1 negative individuals infected with CH077.t-LucR.T2A. The assay cutoff is
depicted as a dotted line in each graph. The box and whiskers graphs represent the 95 percentile, the median is depicted by the line in the box and the maximum
and minimum values are depicted as the whiskers. In addition to the box and whiskers all individual data points are shown as dots.
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infections (RLU) and log inhibition when comparing HIV-1
positive donor cells for both viruses combined as well as when
combining both viruses and both HIV-1 positive and HIV-1
negative donor cells (data not shown), indicating that the
variability observed in the log inhibition is not caused by the
variability in infection. Together these data show that the IMC
LucR VIA has a high specificity that allows for the reliable and
reproducible identification of negative versus positive re-
sponses in the IMC LucR VIA.4. Discussion
Poor correlation between IFN-γ ELISPOT responses and
in vivo control of HIV-1 has triggered the development of the
VIA by several laboratories. The currently used VIA platforms
have limitations with regard to cost, required sample volumes
and assay time. To overcome these obstacleswehave developed
a more efficient, sensitive and cost-effective VIA by the intro-
duction of replication-competent Renilla luciferase reporter
HIV-1 IMC to the VIA. Most importantly, we can reproducibly
identify negative versus positive responses in the IMC LucR VIA,
which is of great importance for the assessment of functional
CD8 T-cell responses in large-scale clinical trial testing, which
will enhance the ability to select the most promising HIV-1
vaccine candidates capable of controlling HIV-1 replication
in vivo.We significantly reduced the non-specific background
inhibition in the IMC LucR VIA, however we were unable to
abolish it completely, which is most likely due to assay
variability and previously described non-cytolytic activity of
CD8 T cells, such as the production of β chemokines MIP-1α,
MIP-1β and RANTES (Cocchi et al., 1995; Berger, 1997) as
well as IL16 (Baier et al., 1995) and SDF-1 (Bleul et al., 1996;
Oberlin et al., 1996). We use expanded CD4 and CD8 T cells
which allow us to test a large number of viruses and time
points with a limited amount of PBMCs. We achieved a high
purity of target and effector cells (88–97%) (Spentzou et al.,
2010), but nonetheless a low percentage of alternative cells
was still present and could be responsible for the observed
non-specific inhibition. The inhibition observed in the first
generation VIA was shown to be predominately MHC class I
dependent (Spentzou et al., 2010), thereby indicating that an
HIV-1 specific cytolytic mechanism is likely responsible. The
highly significant correlation between the first generation
VIA and IMC LucR VIA implies that the same mechanism of
inhibition is measured in the IMC LucR VIA.
We observed donor dependent variability of susceptibility
to infection in Fig. 5, but found it to be independent of HIV-1
infection status of the donor. Variation of HIV-1 susceptibility
of different PBMC donors has been previously observed
(Kaslow et al., 2005) and is most likely due to differences in
donor genetic background. The maximum infection achieved
could influence the final read out of the VIA by reducing the
overall range of the assay and thereby reducing the log
171M.A. Naarding et al. / Journal of Immunological Methods 409 (2014) 161–173inhibition. However, we do not observe correlation between
the maximum infection and the log inhibition in the IMC
LucR VIA. Nevertheless, additional research is needed to
determine the minimum infection required within this assay.
Of note, in the context of antibody neutralization assays, no
correlation was observed between the susceptibility of 75
donor PBMC to infection, and neutralization sensitivity
(Edmonds et al., 2010).
The presence of the luciferase gene in the T/F CH077.t
genome, resulted in decreased virus replication compared to
wild type virus, the extent of which was similar to that
observed for NL-LucR.T2A, as shown here and previously
(Edmonds et al., 2010). The expression of the Nef protein is
not compromised as shown by Western blot analysis for
NL-LucR.T2A (Edmonds et al., 2010), therefore we are able to
determine Nef epitope dependent CD8 T-cell responses.
However, the lucR.T2A.nef configuration generates a Nef
protein with a modified N-terminus. Thus, Nef is likely not
myristylated. However since it retains the basic residues for
membrane association in the N-terminal domain, its overall
function is likely only modestly impaired (Welker et al.,
1998; Bentham et al., 2006), and thus, we would argue that
the modified N-terminus does not preclude meaningful
analyses using the VIA approaches described above. Further
research is ongoing to determine the extent of nef function,
or loss thereof, of these LucR IMCs. In addition, since we
envision application of LucR-IMC to approaches which will
depend on fully functional Nef, we are investigating alterna-
tive molecular approaches which offer wild-type nef expres-
sion while retaining the advantages already realized for
antibody neutralization and CD8 T cell virus inhibition assays.
When comparing the first generation VIA and the IMC
LucR VIA we used IIIB and NL-LucR.T2A, respectively. NL4.3 is
derived from IIIB and sequence analysis revealed a 97%
sequence homology when comparing the sequence of the IIIB
stock to NL4.3 (AF324493) (data not shown). The major
difference is that IIIB does not express the nef gene due to a
frame shift, where NL4.3 has an open nef reading frame, and
thus, NL-LucR.T2 does express Nef, with the modification
discussed above. Overall we believe the genetic differences to
be sufficiently small to allow us to compare results obtained
from these two viruses in the first generation VIA and IMC
LucR VIA, and the significant correlation between the data
supports this conclusion.
We demonstrated relevance of the IMC LucR VIA for clinical
trial sample analysis by testing cells obtained pre and post
HIV-1 vaccination. The pre immunization samples showed
inhibition levels below the cut-off value, while among the post
immunization samples some showed viral inhibition. In
addition we tested an array of HIV-1 positive, LTNP and HIV-1
negative samples. As expected, none of the HIV-1 negative
samples inhibited viral replication above the cut-off.
We describe the optimization of the IMC LucR VIA based on
the use of two “full length” LucR IMCs. Both NL-LucR.T2A and
CH077.t-LucR.T2A are clade B viral isolates. An expansion and
diversification of the viral panel to includemore HIV-1 clades is
necessary to assess the breath of the HIV-1 vaccine induced
CD8 T cell responses. An emphasis on recent T/F viruses, which
are more susceptible to CD8 T cell antiviral responses than
viruses isolated later in infection (Freel et al., 2012), is
recommended as it would be a better representation of thevaccine targets. When testing samples from clinical trials, we
observed that NL-LucR.T2Awas inhibitedmore frequently than
CH077.t-LucR.T2A, although the magnitude of the responses
did not seem to vary (data not shown). The samples used were
from trials of vaccine candidates based on clade B HIV-1 lab
strains HIV-1, which may explain the higher response rate for
the lab strain NL-LucR.T2A than to the T/F virus CH077.t-
LucR.T2A. However, when we looked at samples from HIV-1
positive individuals very similar maximum infections and log
inhibitions were observed for both viruses. It is possible that in
the context of a chronic infection the CD8 T-cell response is
broader. In addition, these individuals are most likely infected
with a non-clade B HIV-1, so the response to clade B viruses
also indicates a broad CD8 T cell response, explaining the very
similar inhibition pattern between the two viruses for these
specific donors.
In summary, we have successfully developed and opti-
mized the IMC LucR VIA using Renilla luciferase-expressing
IMCs containing the full length viral genome. This novel VIA
allows for the determination of HIV-1 specific CD8 T-cell
responses from HIV-1 vaccine trial volunteers by a rapid and
cost effective luciferase read out. Most importantly we have
shown that the IMC LucR VIA has a high degree of specificity,
a reduction of non-specific background inhibition, and an
increase in positive responses, indicating an increase in
sensitivity compared to the first generation VIA. Overall, the
IMC LucR VIA is a novel VIA that can be implemented in
large-scale clinical trial testing to assess functional HIV-1
specific CD8 T cell responses, which will enhance the ability
to select the most promising HIV-1 vaccine candidates
capable of controlling HIV-1 replication in vivo.
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